Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab and tirzepatide in obesity/overweight with type 2 diabetes
NCT06901349Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab and tirzepatide in obesity and type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 36 weeks. Planned start May 2025; status: withdrawn.
02
Drugs
bimagrumabtirzepatide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06901349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901349.